Karyopharm Therapeutics Announces Key Inducement Grants for New Employees

Karyopharm Therapeutics: Investing in Talent

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a prominent player in the pharmaceutical sector focused on innovative cancer treatments, recently shared exciting news regarding employee retention and motivation strategies. On December 1, 2025, the company announced granting inducement stock options and restricted stock units (RSUs) to seven newly joined staff members, aligning with Nasdaq's Listing Rule 5635(c)(4). This step exemplifies Karyopharm's commitment to attracting and retaining top talent crucial for their mission of developing first-in-class cancer therapies.

Details of the Grants

Karyopharm offered stock options allowing the purchase of 2,800 shares of its common stock. Additionally, 15,791 restricted stock units were granted to incentivize new employees under the company's 2022 Inducement Stock Incentive Plan. These options were set at an exercise price of $5.62 per share, reflecting the company's closing stock price on the grant date, November 30, 2025.

The stock options have a vesting schedule over four years, ensuring that 25% of the options will vest on the one-year anniversary of the employee's commencement date. After this, the remaining options will vest monthly at a rate of 1/48th. A crucial condition for this vesting is the continued employment of the staff members with Karyopharm, underscoring the company's desire to build a dedicated workforce.

In addition to stock options, the RSUs will vest over three years, with a third of the shares becoming available at each of the three consecutive anniversaries of the grant date. Similar to the stock options, the vesting of RSUs is contingent on the employees maintaining their roles within the company. This strategy emphasizes Karyopharm's approach to fostering stability and engagement among their workforce.

Karyopharm's Commitment to Innovative Cancer Therapies

Karyopharm Therapeutics, based in Newton, Massachusetts, is dedicated to pioneering groundbreaking therapies for cancer treatment. The company has positioned itself as a leader in addressing nuclear export dysregulation, a critical factor in oncogenesis. Their flagship drug, XPOVIO® (selinexor), has gained approval in the U.S. and is marketed across three oncology indications. Additionally, XPOVIO has acquired regulatory approvals in various international markets, including the European Union and China (under the name NEXPOVIO®).

This commitment is reflected not only in their developmental pipeline but also in their workforce. Karyopharm's engaging culture is designed to attract innovators and thinkers who are as passionate about fighting cancer as they are about clinical breakthroughs. With a focused pipeline addressing multiple cancers with high unmet needs, the company is not just investing in stock options and RSUs; it is investing in futures—both its employees and the thousands of patients relying on effective cancer treatments.

Conclusion

Karyopharm Therapeutics is actively building a workforce equipped to tackle the challenges of cancer treatment. Through strategic inducement grants, the company is ensuring that it maintains a strong, motivated team that is essential for successful drug development and patient outcomes. As Karyopharm continues to grow and evolve in its mission, the significance of such initiatives will only increase, directly impacting the progress in oncology and providing hope for countless patients worldwide.